{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T20:38:50Z","timestamp":1793911130781,"version":"4.8.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.rmed.2026.109211","type":"journal-article","created":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T15:20:15Z","timestamp":1791645615000},"page":"109211","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Real-world effectiveness of dupilumab in patients with severe asthma in Europe: Findings from the EU-ADVANTAGE study"],"prefix":"10.1016","volume":"263","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4645-5209","authenticated-orcid":false,"given":"Arnaud","family":"Bourdin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8467-2557","authenticated-orcid":false,"given":"Giorgio Walter","family":"Canonica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann Christian","family":"Virchow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juby","family":"Jacob-Nara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kinga","family":"Borsos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5795-1147","authenticated-orcid":false,"given":"Richard H.","family":"Stanford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhixiao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Soler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3110-6775","authenticated-orcid":false,"given":"Lynn","family":"Huynh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andra","family":"Boca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5035-6687","authenticated-orcid":false,"given":"Mei Sheng","family":"Duh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Han","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aakash","family":"Gandhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.rmed.2026.109211_bib1","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1183\/09031936.00202013","article-title":"International ERS\/ATS guidelines on definition, evaluation and treatment of severe asthma","volume":"43","author":"Chung","year":"2014","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.rmed.2026.109211_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2019.105859","article-title":"One-year follow up of asthmatic patients newly initiated on treatment with medium- or high-dose inhaled corticosteroid-long-acting \u03b2(2)-agonist in UK primary care settings","volume":"162","author":"Buhl","year":"2020","journal-title":"Respir. Med."},{"issue":"5","key":"10.1016\/j.rmed.2026.109211_bib3","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.jaip.2014.05.002","article-title":"Asthma exacerbation rates in adults are unchanged over a 5-year period despite high-intensity therapy","volume":"2","author":"Schatz","year":"2014","journal-title":"J. Allergy Clin. Immunol. Pract."},{"issue":"1","key":"10.1016\/j.rmed.2026.109211_bib4","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s41533-021-00222-2","article-title":"Uncontrolled asthma: a retrospective cohort study in Japanese patients newly prescribed with medium-\/high-dose ICS\/LABA","volume":"31","author":"Inoue","year":"2021","journal-title":"npj Primary Care Respir. Med."},{"issue":"1","key":"10.1016\/j.rmed.2026.109211_bib6","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12948-021-00146-9","article-title":"Defining type 2 asthma and patients eligible for dupilumab in Italy: a biomarker-based analysis","volume":"19","author":"Canonica","year":"2021","journal-title":"Clin. Mol. Allergy"},{"key":"10.1016\/j.rmed.2026.109211_bib7","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.2147\/JAA.S321212","article-title":"Association between a type 2 inflammatory disease burden score and outcomes among patients with asthma","volume":"14","author":"Price","year":"2021","journal-title":"J. Asthma Allergy"},{"issue":"3","key":"10.1016\/j.rmed.2026.109211_bib8","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00576-2021","article-title":"Type 2 inflammation in asthma and other airway diseases","volume":"8","author":"Maspero","year":"2022","journal-title":"ERJ Open Res"},{"issue":"2","key":"10.1016\/j.rmed.2026.109211_bib9","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.03393-2020","article-title":"Understanding the key issues in the treatment of uncontrolled persistent asthma with type 2 inflammation","volume":"58","author":"Busse","year":"2021","journal-title":"Eur. Respir. J."},{"issue":"1","key":"10.1016\/j.rmed.2026.109211_bib10","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nri3786","article-title":"Type 2 inflammation in asthma--present in most, absent in many","volume":"15","author":"Fahy","year":"2015","journal-title":"Nat. Rev. Immunol."},{"issue":"4","key":"10.1016\/j.rmed.2026.109211_bib11","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1136\/thoraxjnl-2015-207630","article-title":"Comorbidity in severe asthma requiring systemic corticosteroid therapy: cross-sectional data from the Optimum Patient Care Research Database and the British Thoracic Difficult Asthma Registry","volume":"71","author":"Sweeney","year":"2016","journal-title":"Thorax"},{"issue":"2","key":"10.1016\/j.rmed.2026.109211_bib12","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/resp.13730","article-title":"Rational oral corticosteroid use in adult severe asthma: a narrative review","volume":"25","author":"Chung","year":"2020","journal-title":"Respirology"},{"issue":"2","key":"10.1016\/j.rmed.2026.109211_bib13","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1136\/thoraxjnl-2017-210531","article-title":"Healthcare resource use and costs of severe, uncontrolled eosinophilic asthma in the UK general population","volume":"73","author":"Kerkhof","year":"2018","journal-title":"Thorax"},{"key":"10.1016\/j.rmed.2026.109211_bib14","series-title":"Global Initiative for Asthma (GINA)","year":"2024"},{"issue":"5","key":"10.1016\/j.rmed.2026.109211_bib15","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1111\/all.14151","article-title":"Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4R\u03b1 antibody, is required to broadly inhibit type 2 inflammation","volume":"75","author":"Le Floc'h","year":"2020","journal-title":"Allergy"},{"issue":"26","key":"10.1016\/j.rmed.2026.109211_bib17","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.rmed.2026.109211_bib18","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S2213-2600(21)00322-2","article-title":"Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study","volume":"10","author":"Wechsler","year":"2022","journal-title":"Lancet Respir. Med."},{"issue":"26","key":"10.1016\/j.rmed.2026.109211_bib19","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1056\/NEJMoa1804093","article-title":"Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma","volume":"378","author":"Rabe","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.rmed.2026.109211_bib20","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.anai.2023.11.006","article-title":"Real-world effectiveness of dupilumab in patients with asthma: findings from the US ADVANTAGE study","volume":"132","author":"Blaiss","year":"2024","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"10.1016\/j.rmed.2026.109211_bib21","doi-asserted-by":"crossref","first-page":"575","DOI":"10.2147\/JAA.S312123","article-title":"Real-world experience with dupilumab in severe asthma: one-year data from an Italian named patient program","volume":"14","author":"Campisi","year":"2021","journal-title":"J. Asthma Allergy"},{"issue":"7","key":"10.1016\/j.rmed.2026.109211_bib22","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1111\/cea.13614","article-title":"Effectiveness and safety of dupilumab for the treatment of severe asthma in a real-life French multi-centre adult cohort","volume":"50","author":"Dupin","year":"2020","journal-title":"Clin. Exp. Allergy"},{"key":"10.1016\/j.rmed.2026.109211_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2023.107348","article-title":"Severe asthma clinical remission after biologic treatment with anti-IL4\/IL13: a real-life experience","volume":"217","author":"Portacci","year":"2023","journal-title":"Respir. Med."},{"issue":"1","key":"10.1016\/j.rmed.2026.109211_bib24","first-page":"797","article-title":"Early effectiveness of type-2 severe asthma treatment with dupilumab in a real-life setting; a FeNO-driven choice that leads to winning management","volume":"17","author":"Carpagnano","year":"2022","journal-title":"Multidiscip Respir. Med."},{"issue":"2","key":"10.1016\/j.rmed.2026.109211_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.waojou.2023.100746","article-title":"A real-life comparison of pulmonary and nasal outcomes in patients with severe asthma and nasal polyposis treated with T2-biologics","volume":"16","author":"F\u00f6rster-Ruhrmann","year":"2023","journal-title":"World Allergy Organ. J."},{"issue":"4","key":"10.1016\/j.rmed.2026.109211_bib26","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1183\/23120541.01217-2024","article-title":"Real-world comparative effectiveness of biologic therapies in severe asthma: EU-ADVANTAGE","volume":"11","author":"Canonica","year":"2025","journal-title":"ERJ Open Res."},{"key":"10.1016\/j.rmed.2026.109211_bib27","doi-asserted-by":"crossref","first-page":"475","DOI":"10.2147\/JAA.S357086","article-title":"Annual and post-exacerbation Follow-Up of asthma patients in clinical practice - a large population-based study in Sweden","volume":"15","author":"Sandelowsky","year":"2022","journal-title":"J. Asthma Allergy"},{"issue":"4","key":"10.1016\/j.rmed.2026.109211_bib28","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1164\/rccm.201808-1516OC","article-title":"Exacerbation patterns in adults with asthma in England. A population-based study","volume":"199","author":"Bloom","year":"2019","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"13","key":"10.1016\/j.rmed.2026.109211_bib29","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1403291","article-title":"Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma","volume":"371","author":"Bel","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.rmed.2026.109211_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2022.107058","article-title":"Efficacy and safety of dupilumab as add-on therapy for patients with severe asthma: a real-world Dutch cohort study","volume":"206","author":"Thelen","year":"2023","journal-title":"Respir. Med."},{"key":"10.1016\/j.rmed.2026.109211_bib31","doi-asserted-by":"crossref","first-page":"701","DOI":"10.2147\/JAA.S275068","article-title":"Dupilumab efficacy in patients stratified by baseline treatment intensity and lung function","volume":"13","author":"Pavord","year":"2020","journal-title":"J. Asthma Allergy"},{"issue":"11","key":"10.1016\/j.rmed.2026.109211_bib32","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1016\/j.jaip.2022.06.036","article-title":"Dupilumab is effective in patients with moderate-to-severe uncontrolled GINA-defined type 2 asthma irrespective of an allergic asthma phenotype","volume":"10","author":"Rabe","year":"2022","journal-title":"J. Allergy Clin. Immunol. Pract."},{"issue":"26","key":"10.1016\/j.rmed.2026.109211_bib33","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1304048","article-title":"Dupilumab in persistent asthma with elevated eosinophil levels","volume":"368","author":"Wenzel","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.rmed.2026.109211_bib34","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1007\/s12325-023-02479-0","article-title":"A charter to fundamentally change the role of oral corticosteroids in the management of asthma","volume":"40","author":"Haughney","year":"2023","journal-title":"Adv. Ther."},{"issue":"1","key":"10.1016\/j.rmed.2026.109211_bib35","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S2213-2600(21)00352-0","article-title":"Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): a multicentre, open-label, single-arm study","volume":"10","author":"Menzies-Gow","year":"2022","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.rmed.2026.109211_bib36","article-title":"Real-world effectiveness (RWE) of dupilumab in reducing healthcare resource utilization among moderate-to-severe asthma patients","author":"Pawar","year":"2022","journal-title":"Eur Respirat. Soc."},{"key":"10.1016\/j.rmed.2026.109211_bib37","doi-asserted-by":"crossref","DOI":"10.3389\/falgy.2025.1564033","article-title":"Real world evidence of dupilumab effectiveness in a Colombian cohort of patients diagnosed with severe asthma","volume":"6","author":"Al\u00ed-Munive","year":"2025","journal-title":"Front Allergy"},{"issue":"6","key":"10.1016\/j.rmed.2026.109211_bib38","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1007\/s12325-025-03184-w","article-title":"Efficacy of biologics in reducing exacerbations requiring hospitalization or an emergency department visit in patients with moderate or severe, uncontrolled asthma","volume":"42","author":"Panettieri","year":"2025","journal-title":"Adv. Ther."},{"issue":"9","key":"10.1016\/j.rmed.2026.109211_bib39","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1016\/j.jaip.2024.05.052","article-title":"Real-world data on tezepelumab in patients with severe asthma in Germany","volume":"12","author":"Biener","year":"2024","journal-title":"J. Allergy Clin. Immunol. Pract."},{"issue":"7","key":"10.1016\/j.rmed.2026.109211_bib40","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1016\/j.jaip.2022.03.019","article-title":"Characterization of asthma by age of onset: a multi-database cohort study","volume":"10","author":"Baan","year":"2022","journal-title":"J. Allergy Clin. Immunol. Pract."}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611126005809?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611126005809?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T20:17:21Z","timestamp":1793909841000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0954611126005809"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":38,"alternative-id":["S0954611126005809"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2026.109211","relation":{},"ISSN":["0954-6111"],"issn-type":[{"value":"0954-6111","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world effectiveness of dupilumab in patients with severe asthma in Europe: Findings from the EU-ADVANTAGE study","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2026.109211","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"109211"}}